PA-MSHA inhibits proliferation and induces apoptosis in human non-small cell lung cancer cell lines with different genotypes

Zhao,Xinmin; Wu,Xianghua; Yu,Wen; Cai,Xuwei; Liu,Qi; Fu,Xiaolong; Liu,Zhebin; Hu,Dali; Pan,Shiyun; Huang,Qiling

doi:10.3892/mmr.2016.5869

PA-MSHA inhibits proliferation and induces apoptosis in human non-small cell lung cancer cell lines with different genotypes

Authors:
- Xinmin Zhao
- Xianghua Wu
- Wen Yu
- Xuwei Cai
- Qi Liu
- Xiaolong Fu
- Zhebin Liu
- Dali Hu
- Shiyun Pan
- Qiling Huang
View Affiliations

Affiliations: Department of Medical Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China, Department of Medicine, Beijing Wonder Biopharmaceutical Co., Ltd., Beijing 101407, P.R. China
Published online on: October 20, 2016 https://doi.org/10.3892/mmr.2016.5869
Pages: 5369-5376

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study examined the potential of Pseudomonas aeruginosa-mannose sensitive hemagglutinin (PA-MSHA) to inhibit proliferation and induce apoptosis in non‑small‑cell lung cancer (NSCLC) cell lines. It also investigated its mechanisms of action in different genotypes of human NSCLC. A total of three NSCLC cell lines, PC‑9, A549, and NCI‑H1975, were treated with PA‑MSHA at different concentrations. The anti‑proliferative effect of PA‑MSHA was evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cell cycle distribution and apoptosis induced by the treatment were measured by flow cytometry (FCM) with Annexin V/propidium iodide staining. Western blotting was conducted to determine the expression level of apoptosis‑associated proteins. PA‑MSHA was demonstrated to exert a time‑ and concentration‑dependent cytotoxic effect in PC‑9, A549, and NCI‑H1975 cells. The FCM indicated that all the different concentrations of PA‑MSHA used in the present study induce apoptosis and cell cycle arrest of NSCLC cells. Treatment with PA‑MSHA may exert anti‑proliferative effects on NSCLC cells by affecting regulation of the cell cycle and inducing apoptosis that is mediated in part by an intrinsic apoptosis signaling pathway. These data suggest that PA‑MSHA has the potential to inhibit proliferation and induce apoptosis in NSCLC cells. Furthermore, these data provide mechanistic details for the potential application of PA‑MSHA‑based therapeutic strategies for the treatment of different NSCLC genotypes. This present study suggests potential novel strategies to maximize effective therapeutic strategies targeting anti‑epidermal growth factor receptor for future clinical trials.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Desantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
3	Harari PM, Allen GW and Bonner JA: Biology of interactions: Antiepidermal growth factor receptor agents. J Clin Oncol. 25:4057–4065. 2007. View Article : Google Scholar : PubMed/NCBI
4	Hynes NE and Lane HA: ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer. 5:341–354. 2005. View Article : Google Scholar : PubMed/NCBI
5	Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, et al: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 29:2866–2874. 2011. View Article : Google Scholar : PubMed/NCBI
6	Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 21:2787–2799. 2003. View Article : Google Scholar : PubMed/NCBI
7	Engelman JA and Jänne PA: Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 14:2895–2899. 2008. View Article : Google Scholar : PubMed/NCBI
8	Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, et al: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 27:4702–4711. 2008. View Article : Google Scholar : PubMed/NCBI
9	Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Barón AE, Zeng C and Franklin WA: Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 21:3798–3807. 2003. View Article : Google Scholar : PubMed/NCBI
10	Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M, Nishio K and Nakagawa K: Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther. 9:1647–1656. 2010. View Article : Google Scholar : PubMed/NCBI
11	Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, et al: Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial. Lancet Oncol. 13:528–538. 2012. View Article : Google Scholar : PubMed/NCBI
12	Zhao M, Yang M, Ma H, Li X, Tan X, Li S, Yang Z and Hoffman RM: Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res. 66:7647–7652. 2006. View Article : Google Scholar : PubMed/NCBI
13	Maletzki C, Linnebacher M, Kreikemeyer B and Emmrich J: Pancreatic cancer regression by intratumoural injection of live Streptococcus pyogenes in a syngeneic mouse model. Gut. 57:483–491. 2008. View Article : Google Scholar : PubMed/NCBI
14	Baban CK, Cronin M, O'Hanlon D, O'Sullivan GC and Tangney M: Bacteria as vectors for gene therapy of cancer. Bioeng Bugs. 1:385–394. 2010. View Article : Google Scholar : PubMed/NCBI
15	Zhao M, Geller J, Ma H, Yang M, Penman S and Hoffman RM: Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci USA. 104:10170–10174. 2007. View Article : Google Scholar : PubMed/NCBI
16	Crull K and Weiss S: Antibiotic control of tumor-colonizing Salmonella enterica serovar Typhimurium. ExpBiol Med (Maywood). 236:1282–1290. 2011. View Article : Google Scholar
17	Hayashi K, Zhao M, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K and Hoffman RM: Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. J Cell Biochem. 106:992–998. 2009. View Article : Google Scholar : PubMed/NCBI
18	Yam C, Zhao M, Hayashi K, Ma H, Kishimoto H, McElroy M, Bouvet M and Hoffman RM: Monotherapy with a tumortargeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J Surg Res. 164:248–255. 2010. View Article : Google Scholar : PubMed/NCBI
19	Kreikemeyer B, Klenk M and Podbielski A: The intracellular status of Streptococcus pyogenes: Role of extracellular matrix-binding proteins and their regulation. Int J Med Microbiol. 294:177–188. 2004. View Article : Google Scholar : PubMed/NCBI
20	Wang J, Wu D and Chen L: Pseudomonas aeruginosa vaccine inhibits the proliferation of human nasopharyngeal cancer cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao. 32:544–547. 2012.(In Chinese). PubMed/NCBI
21	Liu ZB, Hou YF, Di Min-Dong GH, Wu J, Shen ZZ and Shao ZM: PA-MSHA inhibits proliferation and induces apoptosis through the up-regulation and activation of caspases in the human breast cancer cell lines. J Cell Biochem. 108:195–206. 2009. View Article : Google Scholar : PubMed/NCBI
22	Liu ZB, Hou YF, Zhu J, Hu DL, Jin W, Ou ZL, Di GH, Wu J, Shen ZZ and Shao ZM: Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner. Oncogene. 29:2996–3009. 2010. View Article : Google Scholar : PubMed/NCBI
23	Li Z, Hao D, Zhang H, Ren L, Yang Y, Li L, Chai J, Zhou X and Fu L: A clinical study on PA-MSHA vaccine used for adjuvant therapy of lymphoma and lung cancer. Hua Xi Yi Ke Da Xue Xue Bao. 31:334–337. 2000.(In Chinese). PubMed/NCBI
24	Chen WD, Tang ZH and Xu F: Application of PA-MSHA vaccine adjuvant therapy and TAC scheme for treatment of breast carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 29:1204–1207. 2009.(In Chinese). PubMed/NCBI
25	Philchenkov AA: Caspases as regulators of apoptosis and other cell functions. Biochemistry (Mosc). 68:365–376. 2003. View Article : Google Scholar : PubMed/NCBI
26	Mathiasen IS and Jäättelä M: Triggering caspase-independent cell death to combat cancer. Trends Mol Med. 8:212–220. 2002. View Article : Google Scholar : PubMed/NCBI
27	Tretiakova I, Blaesius D, Maxia L, Wesselborg S, Schulze-Osthoff K, Cinatl J Jr, Michaelis M and Werz O: Myrtucommulone from Myrtus communis induces apoptosis in cancer cells via the mitochondrial pathway involving caspase-9. Apoptosis. 13:119–131. 2008. View Article : Google Scholar : PubMed/NCBI
28	Hegardt C, Andersson G and Oredsson SM: Different roles of spermine in glucocorticoid- and Fas-induced apoptosis. Exp Cell Res. 266:333–341. 2001. View Article : Google Scholar : PubMed/NCBI